Tenax Therapeutics, INC Schedule 13G passive stakes

ING Groep N.V. and ING Capital Markets LLC have filed a Schedule 13G, confirming they beneficially own 0% of Tenax Therapeutics, Inc. common stock as of September 11, 2026.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 14.0% of Tenax Therapeutics, Inc. common stock.

FMR LLC and Abigail P. Johnson have jointly filed an amended Schedule 13G, disclosing beneficial ownership of 1.4% of Tenax Therapeutics Inc.'s common stock as of August 31, 2026.

ING Groep N.V. and its subsidiary ING Capital Markets LLC have reported beneficial ownership of 7.05% of Tenax Therapeutics, Inc. common stock.

Sphera Funds Management Ltd. and its affiliates have reported a beneficial ownership of 5.33% in Tenax Therapeutics, Inc. common stock as of August 17, 2026.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 5.8% of Tenax Therapeutics, Inc. common stock.

Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G, reporting beneficial ownership of 1,080,700 shares, representing 2.9% of Tenax Therapeutics, Inc.'s common stock.

Venrock Healthcare Capital Partners III, L.P. and affiliated entities report a beneficial ownership of 4.7% of Tenax Therapeutics, Inc. common stock, primarily through warrants.

Biotechnology Value Fund and associated entities have disclosed a significant beneficial ownership stake of 9.99% in Tenax Therapeutics, Inc., primarily through pre-funded warrants and warrants.

RTW Investments, LP and Roderick Wong report beneficial ownership of 2,866,654 shares, representing 9.9% of Tenax Therapeutics, Inc.'s common stock, as of June 30, 2026.

Adage Capital Management, L.P. and associated entities have amended their Schedule 13G filing to report beneficial ownership of 6.81% of Tenax Therapeutics, Inc. common stock.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported a 3.3% stake in Tenax Therapeutics, Inc.

T. Rowe Price Associates, Inc. filed an amendment to its Schedule 13G, reporting a beneficial ownership of 2.2% in Tenax Therapeutics, Inc.

Millennium Management LLC and Israel A. Englander have reported a 5.1% beneficial ownership stake in Tenax Therapeutics, Inc.

Logos Global Management LP and affiliated entities have filed a Schedule 13G reporting a 3% beneficial ownership stake in Tenax Therapeutics, Inc.

Stonepine Capital Management, LLC and associated entities have filed a Schedule 13G reporting a 3.7% beneficial ownership stake in Tenax Therapeutics, Inc.

Venrock Healthcare Capital Partners and affiliates have reported a 9.9% beneficial ownership stake in Tenax Therapeutics, Inc. as of March 31, 2026.

Point72 Asset Management and Steven A. Cohen have reported a 3.1% beneficial ownership stake in Tenax Therapeutics, Inc. as of March 31, 2026.

Lind Global Fund II LP and affiliates disclosed a 0.78% beneficial ownership stake in Tenax Therapeutics, Inc. via warrants.

Biotechnology Value Fund and affiliates report a 9.99% beneficial ownership stake in Tenax Therapeutics, Inc. via Schedule 13G filing.

Dellora Investments Master Fund LP, Dellora Investments LP, and Kevin Pyun have collectively reported beneficial ownership of 2.3% of Tenax Therapeutics' common stock as of March 31, 2026.

RTW Investments, LP and Roderick Wong report beneficial ownership of 1,867,630 shares, representing 9.9% of Tenax Therapeutics, Inc. common stock.

Millennium Management and affiliated entities report a 2.1% beneficial ownership stake in Tenax Therapeutics, Inc.

T. Rowe Price Associates, Inc. has reported a beneficial ownership of 11.0% in Tenax Therapeutics Inc., holding 2,841,114 shares of common stock as of April 30, 2026.

T. Rowe Price Associates, Inc. has reported a significant beneficial ownership stake of 17.2% in Tenax Therapeutics Inc., holding 2,951,116 shares of common stock as of March 31, 2026.

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 2.1% of Tenax Therapeutics, Inc. common stock as of March 31, 2026.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G amendment indicating they no longer beneficially own more than five percent of Tenax Therapeutics, Inc. common stock.

Ikarian Capital, LLC and Neil Shahrestani have reported a beneficial ownership of 6.7% in Tenax Therapeutics, Inc. as of March 31, 2026.

Dellora Investments Master Fund LP, Dellora Investments LP, and Kevin Pyun have disclosed beneficial ownership stakes of up to 6.4% in Tenax Therapeutics, Inc.

RTW Investments and Roderick Wong disclose a 9.9% beneficial ownership stake in Tenax Therapeutics, Inc., as detailed in an amended Schedule 13G filing.